An official website of the United States government
Here’s how you know
Official websites use .gov
A
.gov
website belongs to an official government organization in the
United States.
Secure .gov websites use HTTPS
A
lock
(
) or
https://
means you’ve safely connected to the .gov website. Share sensitive
information only on official, secure websites.
Electronic prescribing of controlled substances (EPCS) enables clinicians to securely transmit prescriptions for controlled substances to a pharmacy (1). Prescription drug monitoring programs (PDMPs) are electronic databases that contain patient-specific prescription information, which enables clinicians to view their patients’ prescription history before prescribing contolled substances (2). Together, the use of EPCS and PDMPs can help clinicians make informed treatment decisions. However, these tools are only useful if EPCS is used routintely, and if clinicians check the PDMP prior to prescribing. Recent efforts, such as federally mandated use of EPCS technology (3) and integration of PDMPs into electronic health record (EHR) sytems, have aimed to increase the utility of information contained in PDMPs. This brief provides national estimates of office-based physicians’ use of EPCS and PDMPs in 2021 and explores variation in use by physician characteristics—including specialty, practice size, and frequency of prescribing controlled substances—and describes physician-reported benefits associated with PDMP use.
Figure 1: Physician-reported frequency of checking the PDMP and using EPCS (among those who prescribe controlled substances), 2019-2021

Figure 2: Percent of office-based physicians that check the PDMP (Panel A) and use EPCS technology (Panel B), by frequency of prescribing controlled substances, 2021.

Figure 3: Percent of office-based physician who check the PDMP and use EPCS (among those who prescribe controlled substances), by practice characteristics, 2021.

Figure 4: Percent of office-based physicians who accessed the PDMP through their EHR (among those who prescribe controlled substances and check their state’s PDMP), 2019-2021.

Figure 5: Percent of office-based physicians who access the PDMP through their EHR (among those who prescribe controlled substances and check their state’s PDMP), by EHR vendor, 2021.

Figure 6: Percent of office-based physicians who typically request to view PDMP data from other states prior to prescribing a controlled substance to a patient for the first time (among those who prescribe controlled substances and check their state’s PDMP), 2019-2021.

Table 1: Physician-reported benefits associated with PDMP use (among those who prescribe controlled substances and check their state’s PDMP), 2021
| PDMP Benefits | |
|---|---|
| Reduced or eliminated controlled substance prescriptions for a patient | 59% |
| Confirmed appropriateness of treatment | 54% |
| Confirmed patients’ misuse of prescriptions (e.g., engage in doctor shopping) | 43% |
| Changed controlled substance prescriptions to non-opioid pharmacologic (e.g., NSAIDS or acetaminophen) or non-pharmacologic therapy (e.g., exercise/physical therapy or CBT). | 36% |
| Consulted and/or coordinate with other members of the care team | 26% |
| Referred additional treatment (e.g., substance abuse treatment, psychiatric or pain management) | 28% |
| Consulted with other prescribers listed in PDMP report | 23% |
| Assessed pain and function of patient (e.g., PEG) | 18% |
| Prescribed naloxone | 13% |
| At least 1 reported benefit | 87% |
|---|---|
| Mean number of benefits | 3.0 |
In 2021, more than two-thirds of physicians who prescribed controlled substances used EPCS technology (71%) and more than three-quarters checked their state’s PDMP (78%) prior to prescribing controlled substances to a patient for the first time. While PDMP use remained relatively stable from 2019 to 2021, the percentage of prescribers who reported using EPCS “often” increased significantly from 37% to 62%. The share of prescribers who reported rarely or never using EPCS decreased significantly from 55% to 26%. Further, physicians who more often prescribed controlled substances were more likely to use EPCS. Given the stringent requirements for setting up EPCS (4), infrequent prescribers may have had less motivation to implement such technology unless it was mandated in their state (5). Almost 90% of physicians that used the PDMP reported experiencing a benefit from its use, and on average physicians reported experiencing three distinct benefits. Taken together, these data indicate that EPCS and PDMP use were both widespread and provided substantial benefit.
Despite the significant progress in the use of EPCS among office-based physicians, rates of EPCS use varied significantly by physician specialty, practice size, ownership, and EHR developer market share.
For instance, 2021 rates of EPCS use among physicians working in community health centers more than tripled from 2017 rates (6) and were significantly higher than among physicians working in physician-owned practices. These high rates of engagement may be attributable to funding community health centers received from the Health Resources & Services Administration (HRSA) to support the adoption and advancement of health IT (7) or other similar funding opportunities. This suggests that targeted support may be needed to achieve universal use among physicians in lower-resource settings. PDMP use was less correlated with practice characteristics, potentially because it is not as dependent on support of EHR developers or the resources the practice can commit to implementation.
The integration of PDMPs within EHRs is one effort to promote data sharing and use for authorized users, and may help physician prescribers of controlled substances realize broader benefits from PDMP use as prior work has shown more frequent PDMP use among physicians whose PDMP is integrated with their EHR (8). Yet in contrast to the high level of use of the PDMP and EPCS, the share of physicians who accessed the PDMP through their EHR was relatively low but had increased substantially from 2019. These data indicate the effectiveness of efforts to increase integration and the importance of continuing those efforts (9). Substantial variation by EHR developer indicates that progress is likely not occurring evenly, and that limited capacity of some EHR developers and PDMP developers to support the integration of PDMPs into EHR systems is likely a barrier to its uptake.
Finally, despite physicians’ widespread access to data from their state’s PDMP, the electronic sharing of PDMP data across state lines remains limited and did not change between 2019 and 2021. Querying other state PDMPs – especially bordering states – can be important to capture complete prescription histories of patients who have sought care in different health care systems and geographic locations (10). Interstate querying is one of the major remaining hurdles for PDMP interoperability. As of 2021, most PDMPs were connected to an interstate hub for PDMP data exchange, but only 28 states/territories reported sharing data with more than 30 other states (11). It is worth noting that the share of physicians who check the PDMP and view PDMP data from other states may be shaped by several dynamics at the state or local level: local differences in the perceived value of checking other states (e.g., because of proximity to borders), prescriber use laws that describe the circumstances under which health care providers are required to check the PDMP (12), the capabilities of the PDMP to query neighboring and other states , and the active adoption and use of interstate hubs for PDMP data exchange or the ability to access PDMP data by other means (e.g., through Health Information Exchange organizations).
Electronic Prescribing of Controlled Substances (EPCS) – technology that enables prescribers to securely transmit prescriptions for controlled substances to a pharmacy (1).
EPCS use – physicians’ use of EPCS is defined as sending prescriptions for controlled substances electronically to the pharmacy.
Hospital ownership – includes practices owned by medical/academic health centers and other hospital types.
Insurance company or corporation ownership – includes practices owned by insurance companies, health plans, or HMOs and other health care corporations.
Prescription Drug Monitoring Program (PDMP) – electronic databases that contain patient-specific prescription information, which enables clinicians to view their patients’ prescription dispense history before prescribing contolled substances (2).
PDMP use – physician (or designated staff) use of the PDMP is defined as checking the PDMP prior to prescribing controlled substances to a patient for the first time.
Data come from the 2019 and 2021 National Electronic Health Records Survey (NEHRS). The NEHRS is an annual survey of office-based physicians conducted by the Centers for Disease Control and Prevention’s National Center for Health Statistics. Physicians included in this survey provide direct patient care in office-based practices and community health centers; excluded are those who do not provide direct patient care (radiologists, anesthesiologists, and pathologists).
Among the 10,302 physicians that were initially recruited to complete the 2019 and 2021 surveys, 5,684 were deemed ineligible in 2019 and 3,177 were deemed ineligible in 2021. Among those who were eligible or whose eligibility could not be determined, NCHS estimated an unweighted response rate of 41 percent in 2019 and 47 percent in 2021, yielding a final sample of 1,524 respondents in 2019 and 1,875 respondents in 2021.
Adjustments were made to account for non-response among physicians whose eligibility could not be determined and for those who did not participate in the survey. Responses for the 1,524 records included in the final 2019 survey were weighted to reflect national estimates for approximately 301,603 office-based physicians in the U.S. Responses for the 1,875 records included in the final 2021 survey were weighted to reflect national estimates for approximately 403,013 office-based physicians in the U.S.
Additional survey documentation can be found on the NEHRS website.
The authors are with the Office of Technology, within the Office of the National Coordinator for Health Information Technology. Lolita Kachay and Carmen Smiley, also with the ONC Office of Technology, contributed to the brief. The data brief was drafted under the direction of Mera Choi, Director of the Technical Strategy and Analysis Division, Vaishali Patel, Deputy Director of the Technical Strategy and Analysis Division, and Wesley Barker, Chief of the Data Analysis Branch.
Richwine C. & Everson J. (January 2023). Title. ONC Data Brief, no.63. Office of the National Coordinator for Health Information Technology: Washington DC.
Appendix Table A1: Survey questions assessing physicians’ frequency of prescribing controlled substance, using EPCS, and accessing their state’s PDMP
| Measure | Question Text | Response Options |
|---|---|---|
| Prescribe controlled substances | How frequently do you prescribe controlled substances? |
|
| Use electronic prescribing of controlled substances (EPCS) | How frequently are prescriptions for controlled substances sent electronically to the pharmacy? |
|
| Check prescription drug monitoring program (PDMP) | How frequently do you or designated staff check your state’s prescription drug monitoring program (PDMP) prior to prescribing a controlled substance to a patient for the first time? |
|
| PDMP access method | How do you or your designated staff check your state’s PDMP? |
|
| Interstate data sharing | When checking your state’s PDMP, do you or designated staff typically request to view PDMP data from other states prior to prescribing a controlled substance for the first time? |
|
Appendix Table A2: Physician-reported frequency of prescribing controlled substances, 2019-2021.
| 2019 | 2021 | |
|---|---|---|
| Often | 29% | 28% |
| Sometimes | 31% | 37%* |
| Rarely | 31% | 24%* |
| Never | 8% | 10% |
| Blank | 0% | 0% |
| Don’t know | 1% | 0% |
Appendix Table A3: Percent of office-based physicians that use EPCS, by frequency of prescribing controlled substances, 2019-2021.
| 2019 | 2021 | |
|---|---|---|
| Often | 60%* | 88%* |
| Sometimes(reference) | 49% | 79% |
| Rarely | 24%* | 41%* |
Appendix Table A4: Percent of office-based physicians that check the PDMP, by frequency of prescribing controlled substances, 2019-2021.
| 2019 | 2021 | |
|---|---|---|
| Often | 85% | 85% |
| Sometimes (reference) | 82% | 79% |
| Rarely | 59%* | 69%* |
Appendix Table A5: Percent of office-based physician prescribers of controlled substances that use EPCS technology and check their PDMP, by practice characteristics, 2021.
| Practice characteristics | Use EPCS | Check PDMP |
|---|---|---|
| Practice size | ||
| 1 physician (reference) | 62% | 77% |
| 2-3 physicians | 64% | 80% |
| 4-10 physicians | 76%* | 77% |
| 11 or more physicians | 82%* | 79% |
| Practice ownership | ||
| Physician/Physician group (reference) | 63% | 75% |
| Insurance company or corporation | 90%* | 80% |
| Community Health Center | 83%* | 83% |
| Hospital | 82%* | 86%* |
| Specialty | ||
| Primary Care (reference) | 79% | 80% |
| Surgical | 67%* | 71%* |
| Medical | 61%* | 79% |
| Setting | ||
| Private solo or group practice (reference) | 67% | 77% |
| Other setting | 82%* | 80% |
| Medicare Physicians | ||
| Treat Medicare Patients | 71% | 79% |
| Do Not Treat Medicare Patients | 72% | 71%* |
| Medicaid Physicians | ||
| Treat Medicaid Patients | 73% | 78% |
| Do Not Treat Medicaid Patients | 67% | 79% |
| EHR Vendor Market Share | ||
| 1st-5th market position (reference) | 80% | 80% |
| 6th-10th market position | 72% | 77% |
| All others | 61%* | 73% |
Appendix Table A6: Physician-reported frequency of sending prescriptions for controlled substances electronically to the pharmacy, 2019-2021.
| 2019 | 2021 | |
|---|---|---|
| Use EHR system | 21% | 34%* |
| Use system outside of EHR | 71% | 60% |
| Don’t know | 8% | 6% |
Thank you for visiting the new beta version of the HealthIT.gov website! We’re continuing to make improvements behind the scenes. You may see some features and performance change during this time. We welcome your feedback using the "Submit Feedback" button at the bottom of the page to help us improve your experience!